Home › Companies › CARDIFF ONCOLOGY INC. › 2023-2024
At CARDIFF ONCOLOGY INC.'s shareholder meeting held June 20, 2024, in the 2023-2024 proxy season, 55 asset managers reported how they voted on 10 ballot items in their SEC Form N-PX filings, covering 190 separate fund positions. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, the compensation of the Company's named executive… — CARDIFF ONCOLOGY INC.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CARDIFF ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CARDIFF ONCOLOGY INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 20, 2024: 10 items on CARDIFF ONCOLOGY INC.’s Form 8-K, filed June 20, 2024: 7 elected · 3 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore CARDIFF ONCOLOGY INC. in the interactive database Compare manager voting policies
These tallies are CARDIFF ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark Erlander, Ph.D. | 15,221,656 | 0 | 601,956 | -- | 11,913,370 | 100% | Elected | — |
| Elect Director: Dr. Rodney Markin | 15,518,934 | 0 | 304,679 | -- | 11,913,369 | 100% | Elected | — |
| Elect Director: Dr. James O. Armitage | 15,435,187 | 0 | 388,426 | -- | 11,913,369 | 100% | Elected | — |
| Elect Director: Lale White | 15,277,092 | 0 | 546,520 | -- | 11,913,370 | 100% | Elected | — |
| Elect Director: Gary W. Pace, Ph.D. | 15,370,168 | 0 | 453,445 | -- | 11,913,369 | 100% | Elected | — |
| Elect Director: Mani Mohindru, Ph.D. | 15,370,574 | 0 | 453,039 | -- | 11,913,369 | 100% | Elected | — |
| Elect Director: Renee P. Tannenbaum, Pharm.D. | 15,213,729 | 0 | 609,883 | -- | 11,913,370 | 100% | Elected | — |
| 2. Appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2024 | 27,146,093 | 264,563 | 326,325 | -- | 1 | 99.0% | Approved | — |
| 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 8,150,000 shares | 13,081,695 | 2,390,777 | 351,135 | -- | 11,913,375 | 85% | Approved | — |
| 4. Advisory vote on the compensation of the Company's named executive officers | 13,280,919 | 2,131,944 | 410,747 | -- | 11,913,372 | 86% | Approved | — |
Source: CARDIFF ONCOLOGY INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.
Each item below shows how the 55 asset managers that disclosed a CARDIFF ONCOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Dr. James O. Armitage
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Dr. James O. Armitage”): 15,435,187 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Dr. Rodney Markin
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Dr. Rodney Markin”): 15,518,934 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Gary W. Pace, Ph.D.
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Gary W. Pace, Ph.D.”): 15,370,168 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Lale White
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Lale White”): 15,277,092 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Mani Mohindru, Ph.D.
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Mani Mohindru, Ph.D.”): 15,370,574 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Mark Erlander, Ph.D.
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Mark Erlander, Ph.D.”): 15,221,656 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: Election of Directors Nominees: Renee P. Tannenbaum, Pharm.D.
CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Renee P. Tannenbaum, Pharm.D.”): 15,213,729 for, 0 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
85% Approved · of votes cast
Description as filed by funds: Proposal to approve an amendment to the Company's 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,150,000 shares from 5,150,000 shares.
CARDIFF ONCOLOGY INC.’s own tally for this item (“3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 8,150,000 shares”): 13,081,695 for, 2,390,777 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 8,150,000 shares was approved by the stockholders by the votes set forth in the table below:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Combines 7 wordings of this item as funds reported it.
86% Approved · of votes cast
Description as filed by funds: Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers.
CARDIFF ONCOLOGY INC.’s own tally for this item (“4. Advisory vote on the compensation of the Company's named executive officers”): 13,280,919 for, 2,131,944 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Laurion Capital Management LP | 928,717 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 445,876 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 348,587 | 0 | 0 | 0 | For |
| BlackRock | 319,239 | 0 | 0 | 0 | For |
| Point72 | 147,709 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 129,493 | 0 | 0 | 0 | For |
| EAM Investors, LLC | 58,559 | 0 | 0 | 0 | For |
| State Street | 54,645 | 0 | 0 | 0 | For |
| CAPSTONE INVESTMENT ADVISORS, LLC | 51,190 | 0 | 0 | 0 | For |
| Northern Trust | 42,350 | 0 | 0 | 0 | For |
| Renaissance | 41,737 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 41,727 | 0 | 0 | 0 | For |
| Two Sigma | 38,513 | 0 | 0 | 0 | For |
| T. Rowe Price | 36,500 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 21,368 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 17,694 | 0 | 0 | 0 | For |
| COMMERCE BANK | 17,000 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 16,907 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| RBC Capital Markets, LLC | 15,000 | 0 | 0 | 0 | For |
| Vanguard | 13,841 | 0 | 0 | 0 | For |
| KEYBANK NATIONAL ASSOCIATION/OH | 12,900 | 0 | 0 | 0 | For |
| Citadel | 10,162 | 0 | 0 | 0 | For |
| Security National Bank | 9,767 | 0 | 0 | 0 | For |
| TRUST CO OF OKLAHOMA | 8,400 | 0 | 0 | 0 | For |
Institutional-manager reports, all 52 managers: 2,884,868 for. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.0% Approved · of votes cast
Description as filed by funds: Proposal to ratify BDO USA, P.C. as the Company's independent registered public accountants for fiscal year ending December 31, 2024.
CARDIFF ONCOLOGY INC.’s own tally for this item (“2. Appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2024”): 27,146,093 for, 264,563 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below:”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,120,417 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 736,416 | 0 | 0 | 0 | For |
| Fidelity | 325,938 | 0 | 0 | 0 | For |
| BlackRock | 27,226 | 0 | 0 | 0 | For |
| Charles Schwab | 16,399 | 0 | 0 | 0 | For |
| American Century | 7,946 | 0 | 0 | 0 | For |
| Equitable | 5,176 | 0 | 0 | 0 | For |
| John Hancock | 1,316 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 44,724,591 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.65% |
| 2 | Fidelity | 0.73% |
| 3 | BlackRock | 0.06% |
| 4 | Charles Schwab | 0.04% |
| 5 | American Century | 0.02% |
| 6 | Equitable | 0.01% |
| 7 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Laurion Capital Management LP | 2.08% |
| 2 | MARSHALL WACE, LLP | 1.00% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.78% |
| 4 | BlackRock | 0.71% |
| 5 | Point72 | 0.33% |
| 6 | BLAIR WILLIAM & CO/IL | 0.29% |
| 7 | EAM Investors, LLC | 0.13% |
| 8 | State Street | 0.12% |
| 9 | CAPSTONE INVESTMENT ADVISORS, LLC | 0.11% |
| 10 | Northern Trust | 0.09% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| COMMODORE CAPITAL LP | 12.04% | 13G |
| BlackRock | 8.91% | 13F |
| Vanguard Group | 8.02% | 13F |
| Pfizer, Inc. | 5.39% | DEF14A |
| Pfizer Inc. 13-5315170 | 5.39% | 13G |
| Mark Erlander, Ph.D. | 2.43% | DEF14A |
| Gary W. Pace, Ph.D. | 1.82% | DEF14A |
| Millennium Management | 1.53% | 13F |
| James Levine | 1.12% | DEF14A |
| Goldman Sachs | 1.02% | 13F |
Percentages above are of 44,724,591 shares outstanding, as reported by CARDIFF ONCOLOGY INC. on its Form 10-Q dated April 25, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CARDIFF ONCOLOGY INC.’s 10-Q dated April 25, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CARDIFF ONCOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “CARDIFF ONCOLOGY (CRDF) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cardiff-oncology-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.